KDR and neoplasm: The results demonstrated that both anti-VEGFR2 targeted and non-targeted nanoparticles labeled with 131I were effective in delaying the tumor growth of ATC and that the 131I-labeling anti-VEGFR2 targeted MSNs was the most effective agent to inhibit the tumor growth in nude mice and prolonging median survival.